Literature DB >> 27565002

Photoinduced Mild Hyperthermia and Synergistic Chemotherapy by One-Pot-Synthesized Docetaxel-Loaded Poly(lactic-co-glycolic acid)/Polypyrrole Nanocomposites.

Jie Yuan1, Jialu Liu1, Qi Song1, Dan Wang1, Wensheng Xie1, Hao Yan1, Junfeng Zhou1, Yen Wei1, Xiaodan Sun1, Lingyun Zhao1.   

Abstract

Mild hyperthermia has shown great advantages when combined with chemotherapy. The development of a multifunctional platform for the integration of mild hyperthermia capability into a drug-loading system is a key issue for cancer multimodality treatment application. Herein, a facile one-pot in situ fabrication protocol of docetaxel (DTX)-loaded poly(lactic-co-glycolic acid) (PLGA)/polypyrrole (PPy) nanocomposites was developed. While the PLGA nanoparticles (NPs) allow efficient drug loading, the PPy nanobulges embedded within the surface of the PLGA NPs, formed by in situ pyrrole polymerization without the introduction of other template agents, can act as ideal mediators for photoinduced mild hyperthermia. Physiochemical characterizations of the as-prepared nanocomposites, including structure, morphology, photothermal effects, and an in vitro drug release profile, were systematically investigated. Further, 2-deoxyglucose-terminated poly(ethylene glycol) (PEG) was anchored onto the surface of the nanocomposites to endow the nanoplatform with targeting ability to tumor cells, which resulted in a 17-fold increase of NP internalization within human breast cancer cells (MCF-7) as competed with PEG-modified nanocomposites. Mild hyperthermia can be successfully mediated by the nanoplatform, and the temperature can be conveniently controlled by careful modulation of the PPy contents within the nanocomposites or the laser power density. Importantly, we have demonstrated that MCF-7 cells, which are markedly resistant to heat treatment of traditional water-bath hyperthermia, became sensitive to the PLGA/PPy nanocomposite-mediated photothermal therapy under the same mild-temperature hyperthermia. Moreover, DTX-loaded PLGA/PPy-nanocomposite-induced mild hyperthermia can strongly enhance drug cytotoxicity to MCF-7 cells. Under the same thermal dose, photoinduced hyperthermia can convert the interaction between hyperthermia and drug treatment from interference to synergism. This is the first report on the one-pot synthesis of PLGA/PPy nanocomposites by in situ pyrrole polymerization, and such a multifunctional nanoplatform is demonstrated as a high-potential agent for photoinduced mild hyperthermia and enhanced chemotherapy.

Entities:  

Keywords:  NIR thermotherapy; PLGA/PPy nanocomposites; docetaxel; mild-temperature hyperthermia; multifunctional nanoplatform

Mesh:

Substances:

Year:  2016        PMID: 27565002     DOI: 10.1021/acsami.6b07669

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  5 in total

1.  Melatonin potentiates "inside-out" nano-thermotherapy in human breast cancer cells: a potential cancer target multimodality treatment based on melatonin-loaded nanocomposite particles.

Authors:  Wensheng Xie; Qin Gao; Dan Wang; Wei Wang; Jie Yuan; Zhenhu Guo; Hao Yan; Xiumei Wang; Xiaodan Sun; Lingyun Zhao
Journal:  Int J Nanomedicine       Date:  2017-10-11

Review 2.  Nanomedicine potentiates mild photothermal therapy for tumor ablation.

Authors:  Zijun Jiang; Tianyi Li; Hao Cheng; Feng Zhang; Xiaoyu Yang; Shihao Wang; Jianping Zhou; Yang Ding
Journal:  Asian J Pharm Sci       Date:  2021-10-15       Impact factor: 6.598

Review 3.  Low-Temperature Photothermal Therapy: Strategies and Applications.

Authors:  Xiulin Yi; Qiu-Yi Duan; Fu-Gen Wu
Journal:  Research (Wash D C)       Date:  2021-05-07

Review 4.  PLGA-Based Nanoparticles in Cancer Treatment.

Authors:  Sima Rezvantalab; Natascha Ingrid Drude; Mostafa Keshavarz Moraveji; Nihan Güvener; Emily Kate Koons; Yang Shi; Twan Lammers; Fabian Kiessling
Journal:  Front Pharmacol       Date:  2018-11-02       Impact factor: 5.810

5.  Tailored Black Phosphorus for Erythrocyte Membrane Nanocloaking with Interleukin-1α siRNA and Paclitaxel for Targeted, Durable, and Mild Combination Cancer Therapy.

Authors:  Wenquan Ou; Jeong Hoon Byeon; Zar Chi Soe; Bo Kyun Kim; Raj Kumar Thapa; Biki Gupta; Bijay Kumar Poudel; Sae Kwang Ku; Chul Soon Yong; Jong Oh Kim
Journal:  Theranostics       Date:  2019-09-19       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.